Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;133(5):3126-3138.
doi: 10.1111/jam.15773. Epub 2022 Aug 18.

Bacillus sp. DU-106 ameliorates type 2 diabetes by modulating gut microbiota in high-fat-fed and streptozotocin-induced mice

Affiliations

Bacillus sp. DU-106 ameliorates type 2 diabetes by modulating gut microbiota in high-fat-fed and streptozotocin-induced mice

Jing Yan et al. J Appl Microbiol. 2022 Nov.

Abstract

Aims: Type 2 diabetes (T2D) is a chronic disease that manifests as endocrine and metabolic disorders that seriously threatening public health. This study aimed to investigate the effects of Bacillus sp. DU-106 on anti-diabetic effects and gut microbiota in C57BL/6J mice fed a high-fat diet and streptozotocin-induced T2D.

Methods and results: Bacillus sp. DU-106 was administered to model mice for eight consecutive weeks. Oral administration of Bacillus sp. DU-106 decreased food and water intake and alleviated body weight loss. Moreover, Bacillus sp. DU-106 imparted several health benefits to mice, including balanced blood glucose, alleviation of insulin resistance in T2D mice and an improvement in lipid metabolism. Furthermore, Bacillus sp. DU-106 protected against liver and pancreatic impairment. Additionally, Bacillus sp. DU-106 treatment reshaped intestinal flora by enhancing gut microbial diversity and enriching the abundance of certain functional bacteria.

Conclusion: Collectively, these findings suggest that Bacillus sp. DU-106 can ameliorate T2D by regulating the gut microbiota.

Significance and impact of study: Therefore, a novel probiotic, Bacillus sp. DU-106 may be a promising therapeutic agent for improving and alleviating T2D in mice.

Keywords: Bacillus sp. DU-106; gut microbiota; hyperglycaemic; metformin; probiotics; type 2 diabetes.

PubMed Disclaimer

References

REFERENCES

    1. Abdellatif, A.M. & Sarvetnick, N.E. (2019) Current understanding of the role of gut dysbiosis in type 1 diabetes. Journal of Diabetes, 11, 632-644.
    1. Cao, Y., Chen, X., Sun, Y., Shi, J., Xu, X. & Shi, Y.C. (2018) Hypoglycemic effects of pyrodextrins with different molecular weights and digestibilities in mice with diet-Induced obesity. Journal of Agricultural and Food Chemistry, 66, 2988-2995.
    1. Chen, C., You, L.J., Huang, Q., Fu, X., Zhang, B., Liu, R.H. et al. (2018) Modulation of gut microbiota by mulberry fruit polysaccharide treatment of obese diabetic db/db mice. Food & Function, 9, 3732-3742.
    1. Chen, P., Zhang, Q., Dang, H., Liu, X., Tian, F., Zhao, J. et al. (2014) Oral administration of Lactobacillus rhamnosus CCFM0528 improves glucose tolerance and cytokine secretion in high-fat-fed, streptozotocin-induced type 2 diabetic mice. Journal of Functional Foods, 10, 318-326.
    1. De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Vinera, J., Zitoun, C., Duchampt, A. et al. (2014) Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell, 156, 84-96.